JPRN-UMIN000006541
Completed
未知
A randomized trial of postoperative adjuvant chemotherapy with capecitabine versus capecitabine/PSK following curative resection for stage III colon cancer. - A randomized trial of postoperative adjuvant chemotherapy with capecitabine versus capecitabine/PSK following curative resection for stage III colon cancer.
Gunma University Graduate School of Medicine Department of Thoracic and Visceral Organ Surgery0 sites70 target enrollmentOctober 14, 2011
ConditionsColon cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Colon cancer
- Sponsor
- Gunma University Graduate School of Medicine Department of Thoracic and Visceral Organ Surgery
- Enrollment
- 70
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\.Synchronous or metachronous colorectal cancer. 2\.History of hypersensitivity for capecitabine drug product component or fluorouracil. 3\.Patients who need continuing use of warfarin potassium and phenytoin. 4\.History of serious drug allergy (\>\= grade 3\). 5\.Patients with severe complication (such as ileus, interstitial lung disease, lung fibrosis, diabetes that is difficult to control, heart failure, renal failure, liver failure). 6\.Female who are pregnant, nursing, suspected of being pregnant or hope to become pregnant during the study period 7\.No birth\-control. 8\.HIV positive. 9\.Not suitable for participating in the study for any other reason.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high risk of relapse based on the Pervenio? Lung RS AssayCompletely resected stage I non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 14.1Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-001494-24-ESEncore Clinical, Inc1,050
Active, not recruiting
Phase 1
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10029517Term: Non-small cell lung cancer stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029518Term: Non-small cell lung cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-001494-24-FRIFCT1,050
Recruiting
Phase 1
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as High or Intermediate Risk by a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lungcancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code: 10025050Term: Lung cancer non-small cell stage I Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10025051Term: Lung cancer non-small cell stage II Class: 10029104MedDRA version: 20.0Level: LLTClassification code: 10025044Term: Lung cancer Class: 10029104MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10079440Term: Non-squamous non-small cell lung cancer Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]CTIS2024-511185-37-00Razor Genomics Inc.915
Active, not recruiting
Phase 1
Clinical trial with or without chemotherapy after surgical resection of the primary lung cancer in patients with high or intermediate risk of relapse based on a 14-Gene Prognostic AssayCompletely resected stage I or IIA non-squamous non-small cell lung cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10025044Term: Lung cancerSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-001494-24-DERazor Genomics, Inc.1,050
Completed
Phase 2
A phase II trial of postoperative adjuvant chemotherapy with carboplatin/ docetaxel for the patients completely resected Non Small Cell Lung Cancernon-small cell lung cancerJPRN-UMIN000002425niversity of Occupational and Environmental Health65